Phase 2 N=41 Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Breast Neoplasms
Primary: Objective Response (OR) — 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=129 A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Fasting Plasma Glucose — 6.0; -0.5; -20.0; -16.0 mg/dL — p=0.4195
Phase 2 N=25 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
Glioblastoma · Astrocytoma · Oligodendroglioma
Primary: Progression-free Survival at 6-months — 17.3 percentage of participants
Phase 2 N=14 Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Leukemia
Primary: Dose-limiting Toxicity — 0; 0 participants
Phase 2 N=594 Improving Treatment Adherence in HIV-Infected Individuals
HIV Antiretroviral Therapy (ART) Adherence · Health Behavior
Primary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12
Phase 2 N=120 Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer
Fungal Keratitis
Primary: Best Spectacle Corrected Visual Acuity (BSCVA) 3 Months After Enrollment, Adjusting for Enrollment BSCVA in a Multiple Linear Regression Model — 0.61; 0.71 logMAR — p=0.29
Phase 2 N=61 Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Tumor Response — 7; 30; 12; 6 participants
Phase 2 N=19 A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
Lymphoma · Cancer
Primary: Summary of Participants With Treatment Emergent Adverse Events (TEAEs) — 18; 14; 11; 0 Participants
Phase 2 N=332 Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use
Tobacco Use Disorder
Primary: Percent Abstinent From Tobacco at Week 12 (7 Day Point Prevalence) — 31; 17 percentage of randomized — p=0.04
Phase 2 N=20 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
Recurrent Thyroid Cancer · Stage IV Follicular Thyroid Cancer · Stage IV Papillary Thyroid Cancer
Primary: Tumor Major Response Rate (Including Stable Disease) as Measured by RECIST Criteria — 10; 1 participants
Phase 2 N=52 Improving the Efficacy of Anti-Nicotine Immunotherapy
Nicotine Dependence
Primary: Vaccine-Induced Percent Change in Brain Nicotine Area Under Curve (AUC) After Single or Multiple (7) Puffs — 1; -15; -0.2; 0.1 percentage of change
Phase 2 N=11 Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.
Myelodysplastic Syndromes
Primary: Number of Participants With Adverse Events (AE) — 11; 11; 11; 11 participants
Phase 2 N=74 Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
Major Depressive Disorder
Primary: Number of Patients With Adverse Events (AEs) — 64; 1; 5; 16 participants
Phase 2 N=57 Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)
Multiple Myeloma
Primary: Overall Response Rate (ORR) - Percentage of Participants With Partial Response or Better With Induction Regimen — 77.2 percentage of participants
Phase 2 N=81 Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: The Primary Safety and Tolerability Outcome Measure is Reported Adverse Events. — 81 participants